EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

TET2-mutant clonal hematopoiesis enhances macrophage antigen presentation and improves immune checkpoint therapy in solid tumors

Shelley Herbrich, Mehdi Chaib, Swetha Anandhan, Samuel W Andrewes, Ashwat Nagarajan, Baoxiang Guan, Nishant Gandhi, Jared Gilliam, Milan Radovich, Padmanee Sharma

Cancer Cell · 2026-01 · 44 (1) · 187-202.e7

DOI: 10.1016/j.ccell.2025.09.011 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Cell, 2026-01. Verfasst von Shelley Herbrich und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Hauptthemen laut MEDLINE: DNA-Binding Proteins, Clonal Hematopoiesis, Proto-Oncogene Proteins, Macrophages. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clonal hematopoiesis (CH) is detectable in upwards of 20% of patients with solid tumors and is associated with worsened prognosis; however, its role in tumor immunology and immune checkpoint therapy (ICT) is unknown. Using a bone marrow chimera model of Tet2+/mut CH in mice with solid tumors, we found the Tet2-mutant myeloid cells are abundant in the tumor microenvironment and contributed to an improved response to ICT. Mechanistically, Tet2+/mut macrophages inside the tumor act as immunogenic antigen-presenting cells that more effectively cross-prime naive CD8+ T cells in response to IFNγ. In human cohorts of 35,971 non-small cell lung cancer patients and 25,064 colorectal adenocarcinoma patients, TET2-mutant CH is associated with improved outcome specifically with ICT. This study proposes a role for Tet2+/mut antigen presenting macrophages in shaping antitumor immunity and identifies TET2-mutant CH as a potential biomarker for improved response to ICT in patients with solid tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DNA-Binding ProteinsClonal HematopoiesisProto-Oncogene ProteinsMacrophagesImmune Checkpoint InhibitorsAntigen PresentationNeoplasmsDioxygenasesAnimalsHumansMiceTumor MicroenvironmentMutationMice, Inbred C57BLFemaleColorectal NeoplasmsCD8-Positive T-LymphocytesCarcinoma, Non-Small-Cell Lung

Stichwörter der Autor:innen

TET2antigen presentationclonal hematopoiesiscross-primingimmune checkpoint therapytumor immunology

Substanzen

DioxygenasesDNA-Binding ProteinsTET2 protein, humanProto-Oncogene ProteinsImmune Checkpoint InhibitorsTet2 protein, mouse

Autor:innen und Institutionen

  • Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Department of Immunology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Yosemite San Francisco, San Francisco, CA, USA.
  • Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; The University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Science…
  • Caris Life Sciences, Irving, TX, USA.
  • Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Immunology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center…

Förderung

  • NCI NIH HHS
  • NIH HHS
  • National Institutes of Health
  • Parker Institute for Cancer Immunotherapy

Zitieren

APA

Herbrich, S., Chaib, M., Anandhan, S., Andrewes, S. W., Nagarajan, A., Guan, B., Gandhi, N., Gilliam, J., Radovich, M., & Sharma, P. (2026). TET2-mutant clonal hematopoiesis enhances macrophage antigen presentation and improves immune checkpoint therapy in solid tumors. Cancer Cell, 44(1), 187-202.e7. https://doi.org/10.1016/j.ccell.2025.09.011

Vancouver

Herbrich S, Chaib M, Anandhan S, Andrewes SW, Nagarajan A, Guan B, et al. TET2-mutant clonal hematopoiesis enhances macrophage antigen presentation and improves immune checkpoint therapy in solid tumors. Cancer Cell. 2026;44(1):187-202.e7. doi:10.1016/j.ccell.2025.09.011

BibTeX
@article{Herbrich2026,
  author = {Herbrich, Shelley and Chaib, Mehdi and Anandhan, Swetha and Andrewes, Samuel W and Nagarajan, Ashwat and Guan, Baoxiang and Gandhi, Nishant and Gilliam, Jared and Radovich, Milan and Sharma, Padmanee},
  title = {TET2-mutant clonal hematopoiesis enhances macrophage antigen presentation and improves immune checkpoint therapy in solid tumors},
  journal = {Cancer Cell},
  year = {2026},
  volume = {44},
  number = {1},
  pages = {187--202.e7},
  doi = {10.1016/j.ccell.2025.09.011}
}
Kostenlos starten →